Seattle Genova
Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990
Email: info@seattle-genova.com Web: www.seattle-genova.com
Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

BioActive Human CCND2 amplification Recombinant Protein,Fc Tag

Catalog Number:SGRP00694

DESCRIPTION	
Product Name	BioActive Human CCND2 amplification Recombinant Protein,Fc Tag
Gene Name	CCND2
Source	Full length Human CCND1 amplification, expressed in HEK293 cells.
Alternative names	
SPECIFICATIONS	
Biological Activity	Fully biologically active
Purity	> 95% by SDS-PAGE & HPLC
Endotoxin Level	< 1.0 EU per μg protein as determined by the LAL method
Expression System	HEK293 Cells
Format	Recombinant
Species	Human
Predicted MW	
Actual MW	
Applications	Sandwich ELISA Functional Studies Mass Spectrometry SDS-PAGE HPLC
Form	Lyophilized from sterile PBS, pH 7.77
Concentration	N/A
Stability and Storage	Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	Reconstitute with Phosphate Buffered Saline.
BACKGROUND	
Gene Accession	P30279
Gene Alias	Protein names Recommended name G1/S-specific cyclin-D2 1 Publication Gene names Name CCND2 1 PublicationImported

	cell tumor, breast invasive ductal carcinoma, rectal adenocarcinoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence.
Background	Cyclin D2 (CCND2) is a gene that encodes for a protein that functions in the regulation of CDK kinases in the cell cycle. Fusions, missense, nonsense, and silent mutations are observed in cancers such as esophageal cancer, skin cancer, and stomach cancer. CCND2 is altered in 1.38% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, testicular mixed germ cell tumor, and rectal adenocarcinoma having the greatest prevalence of alterations. CCND2 Amplification is present in 0.89% of AACR GENIE cases, with colon adenocarcinoma, testicular mixed germ